DocGo Inc. (DCGO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

DocGo Inc. (DCGO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously announced, DocGo Inc. (the “Company”) is conducting a search for a new Chief Executive Officer as the employm

Event · Exec change
Person
Lee Bienstock
Title
Chief Executive Officer
Effective
March 31, 2027

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 13, 2026, 10:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$DCGO
Bearish
high confidence
Mentioned
$DCGO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DCGOBearishLow
01

Why it matters

The filing provides the first public disclosure of the CEO's exit terms, introducing new cost and governance considerations for investors.

02

Market read

Primary disclosure of executive transition for a micro‑cap; likely modest negative impact on stock price.

03

What to watch

Potential upside if the new CEO is identified quickly and brings strategic initiatives; also, the $90k monthly salary may be seen as a cost‑controlled bridge.

Relevance 6/10Novelty 6/10Timing: effective immediately, transition period starts Jan 1 2027

Background

DocGo Inc. filed a Form 8‑K reporting the departure terms of its current CEO, including a transition services agreement, continued advisory role, and severance details.

Company-level read

Ticker impact

$DCGOBearishHigh confidence
Context

SEC 8‑K filing discloses CEO Lee Bienstock's transition agreement, continued service, and a $785k severance package.

Expected impact

likely downward pressure as investors price in higher costs and potential leadership gap

Evidence & confidence

Primary filing with concrete compensation figures; market typically reacts negatively to unexpected executive turnover and sizable severance for a micro‑cap.

Market effects

Minimal; executive change is specific to DocGo and does not affect the broader logistics/technology sector.

None; the company is US‑based and micro‑cap with limited regional influence.

Low; no broader market or macro implications.

Counterpoint

If the transition agreement ensures continuity and the severance is modest relative to cash reserves, the market may view the news as a stabilizing factor.

Key entities

  • Lee Bienstock

    Current CEO of DocGo Inc., subject of the transition and severance agreement.

Related articles

$DCGOMed

DocGo Inc (DCGO) (Q3 2026) Earnings Call Highlights: First Revenue Growth Since 2023

DocGo Inc (DCGO) reported its first revenue growth since 2023 in Q3 2026, with expectations of continued growth in 2027. The company anticipates positive EBITDA for 2027, driven by revenue gains in medical transportation and mobile health lines. DocGo is also focusing on restructuring and renegotiating contracts to improve profitability. The company is awaiting regulatory approval for the Hycuity Health acquisition, expected to close by the end of November.

$DCGOMed

DocGo Announces Third Quarter 2026 Results

DocGo Inc. (DCGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 DocGo Announces Third Quarter 2026 Results Gross Margin Improves 280 Basis Points Over Q2 Due to Company Profitability Initiatives Board of Directors Initiates CEO Search as Lee Bienstock's Employment Contract Expires at Year-End; Lee Bienstock to Continue as CEO and

Med

DocGo Inc. Q2 2026 Earnings Call Summary

DocGo Inc. reported Q2 2026 earnings, highlighting a 19% year-over-year revenue increase in core business lines, despite a $6.3M adjusted EBITDA loss. The company announced its largest acquisition, Hicuity Health, aiming to integrate hospital and home care. Management expects to achieve positive adjusted EBITDA by year-end 2026, with revenue guidance narrowed to $305M-$310M. Cost synergies and efficiency programs are expected to drive future growth.